Using MRI scans to target biopsies is more effective at detecting prostate cancers that are likely to need treatment than standard ultrasound guided biopsies alone, according to research published in JAMA Network Open. The research, led by the National Institute for Health Research (NIHR) and Universities of Bristol, Ottawa, Exeter and Oxford, combined the results from seven studies covering…
A new study has begun to test whether broccoli and garlic can help improve prostate health. The Norfolk Accumulation of Dietary Bioactives and Prostate Cancer (ADaPt) study has been launched by researchers at Quadram Institute Bioscience (QIB) and the Norfolk and Norwich University Hospital (NNUH). The study, which will take place at the NNUH-run Clinical Research Facility at the Quadram…
Prostate-specific membrane antigen imaging should be the positron emission tomography imaging agent of choice for men who have a prostate cancer recurrence after radical prostatectomy, which needs to be detected and located. For these men, it should become the standard of care, new research shows.
Image analysis of prostate cancer is a challenging area for clinicians. The disease shows a low mutation burden compared to melanoma and stomach cancer, for example, making morpho-molecular correlation more difficult, and there is often very low inflammation. With the role of tumour infiltrating lymphocytes in prostate cancer currently unclear – and with the advent of new approaches to prostate…
Wilmot Cancer Institute scientists believe they have figured out why a commonly used drug to treat late-stage prostate cancer often stops working after four or five months and appears to have a dual function that later turns the cancer into a relentless aggressor.
Pathologists, radiologists, urologists and radiotherapy specialists sit at the core of the treatment pathway for the patient, working together as a cohesive unit. In an innovative 2019 ECR session in Vienna, the prostate unit from Ghent University Hospital in Belgium outlined how the team works to deliver the best clinical outcome for patients.
A single high dose of radiation that can be delivered directly to the tumour within a few minutes is a safe and effective technique for treating men with low risk prostate cancer, according to a study presented at the ESTRO 38 conference. Radiotherapy traditionally involves a series of lower dose treatments that take place over several days or week. The new treatment is called high dose-rate…
New medical software which overlays tumour information from MRI scans onto ultrasound images is helping to improve detection of prostate cancer by guiding surgeons as they conduct biopsies. Developed at University College London (UCL), the software is deployed via a system called SmartTarget and embraces artificial intelligence (AI) to use both systems in tandem to enable surgeons to pick up…
A team of researchers from the Icahn School of Medicine at Mount Sinai and Keck School of Medicine at the University of Southern California (USC) have developed a novel machine-learning framework that distinguishes between low- and high-risk prostate cancer with more precision than ever before. The framework, described in a Scientific Reports paper, is intended to help physicians—in particular,…
A pathology test that applies artificial intelligence (AI) to characterize tissue samples can accurately predict clinically significant prostate cancer disease progression following surgery, according to a study conducted at the Icahn School of Medicine at Mount Sinai.
Magnets may play a central role in the future of surgery. This summer, US surgeon Dr. Jeffrey Cadeddu performed the first of several magnet-assisted prostate cancer surgeries he has now done. “Every hole you create in a patient has a risk associated with it. Every incision means increased pain, increased risk of hitting a blood vessel,” days Dr. Cadeddu. The new magnetic approach might prove…
Using high energy ultrasound beams to destroy prostate cancer tumours may be as effective as surgery or radiotherapy, but with fewer side effects. A new study, carried out at six hospitals across the UK, tracked 625 men with prostate cancer who received a type of treatment called high-intensity focused ultrasound (HIFU).
Two blood tests can predict which subset of men with advanced prostate cancer will likely not benefit from anti-androgen therapies, providing doctors and patient added clarity on treatment options, according to a study led by Duke Cancer Institute.
ProteoMediX AG announced results from a retrospective study that showed the correlation of its prostate cancer diagnosis test with cancer aggressiveness in patients scheduled for prostate biopsies. The study findings presented at the 2018 European Association of Urology (EAU) congress in Copenhagen, Denmark showed that the test has the potential to avoid a large number of biopsies. “Correlation…
Prostate cancer is one of the most common cancers diagnosed nationally among men. The National Cancer Institute estimates 161,000 were diagnosed in 2017. While there are many treatment options for men with prostate cancer, a recent national study published in the Journal of the American Medical Association compared the effectiveness of treatments for high-risk prostate cancer. Said Daniel Krauss,…
Radiation therapy is a popular and effective treatment for many men with prostate cancer, and now a temporary gel offers greater protection for organs at risk during treatments. “Treating prostate cancer with radiation therapy can cause unintended injury to adjacent, healthy tissue, which can lead to bowel and urinary problems, as well as erectile dysfunction,” said Daniel Krauss, M.D., a…
A new score for predicting a man’s genetic risk of developing aggressive prostate cancer could help guide decisions about who to screen and when, say researchers in The BMJ today. Prostate cancer is the most frequently diagnosed cancer in males in developed countries, with over a million new cases and over 300,000 associated deaths estimated worldwide in 2012. Screening for prostate specific…
Lars Schimmöller MD, associate professor of radiology at Düsseldorf University Hospital, tackled current diagnosis of prostate cancer (PCa) and addressed tumour detection, staging, active surveillance and recurrence during the Medica Academy session on Imaging Update. He also highlighted how MRI helps improve biopsies and avoid unnecessary surgery in PCa.
The Netherlands Cancer Institute (NKI) announced that it has received funding from the Dutch Cancer Society to test whether a novel molecular imaging technology can guide prostate cancer surgery. The project will evaluate the imaging technology’s ability to detect prostate cancer during surgery, with the aim of performing more accurate removal of cancerous tissue. Prostate cancer is the most…
Johns Hopkins Kimmel Cancer Center scientists report they have discovered a biochemical process that gives prostate cancer cells the almost unnatural ability to change their shape, squeeze into other organs and take root in other parts of the body.
A major 20-year study provides further evidence that prostate cancer surgery offers negligible benefits to many men with early-stage disease. In such men, who account for most cases of newly diagnosed prostate cancer, surgery did not prolong life and often caused serious complications such as infection, urinary incontinence and erectile dysfunction.
Doctors have found that treating prostate cancer with a single, high dose of radiation delivered precisely to the site of the tumour results in good quality of life and fewer trips to the hospital, with adverse side effects that are no worse than if the radiation treatment had been given in several lower doses.
Scientists at a UK university are using the power of mass spectrometry to research critical processes in human prostate cancer.
University of Adelaide researchers have uncovered a new pathway which regulates the spread of prostate cancer around the body.
An international group of researchers report success in mice of a method of using positron emission tomography (PET) scans to track, in real time, an antibody targeting a hormone receptor pathway specifically involved in prostate cancer.